These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35329982)

  • 21. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
    Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
    De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S
    Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventive Treatment of Migraine.
    Lipton RB
    Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real world considerations for newly approved CGRP receptor antagonists in migraine care.
    Scuteri D; Tonin P; Nicotera P; Bagetta G; Corasaniti MT
    Expert Rev Neurother; 2022 Mar; 22(3):221-230. PubMed ID: 35240905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Focus on zavegepant: the first intranasal third-generation gepant.
    Scuteri D; Tarsitano A; Tonin P; Bagetta G; Corasaniti MT
    Pain Manag; 2022 Nov; 12(8):879-885. PubMed ID: 36189708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in Pharmacotherapy for Episodic Migraine.
    Chan C; Goadsby PJ
    CNS Drugs; 2019 Nov; 33(11):1053-1071. PubMed ID: 31556018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.
    Alsaadi T; Suliman R; Santos V; Al Qaisi I; Carmina P; Aldaher B; Haddad S; Bader Y
    Neurol Ther; 2024 Apr; 13(2):465-473. PubMed ID: 38361080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ubrogepant to treat migraine.
    Dhir A
    Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating rimegepant for the treatment of migraine.
    de Vries T; Al-Hassany L; MaassenVanDenBrink A
    Expert Opin Pharmacother; 2021 Jun; 22(8):973-979. PubMed ID: 33648385
    [No Abstract]   [Full Text] [Related]  

  • 32. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
    Dubowchik GM; Conway CM; Xin AW
    J Med Chem; 2020 Jul; 63(13):6600-6623. PubMed ID: 32058712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.
    Holland PR; Goadsby PJ
    Neurotherapeutics; 2018 Apr; 15(2):304-312. PubMed ID: 29556965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Medications for the Treatment of Migraine.
    Ceriani CEJ; Wilhour DA; Silberstein SD
    Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.
    Blumenfeld A; Durham PL; Feoktistov A; Hay DL; Russo AF; Turner I
    Neurol Ther; 2021 Dec; 10(2):469-497. PubMed ID: 34076848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.
    Rubio-Beltran E; Chan KY; Danser AJ; MaassenVanDenBrink A; Edvinsson L
    Cephalalgia; 2020 Apr; 40(4):357-366. PubMed ID: 31674221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
    Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ubrogepant for the treatment of migraine.
    Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.